NIH scientists report a novel opioid, DFNZ, that in rodents produced sustained pain relief for over two hours while, unusually for a mu‑opioid agonist, failing to depress respiration or produce clear withdrawal signs; the team led by Dr. Michael Michaelides at NIH’s National Institute on Drug Abuse says the next major checkpoint is whether those safety signals hold up in human studies.
What the rodent data showed
In multiple preclinical experiments, DFNZ delivered potent analgesia lasting more than two hours even though drug levels in the brain fell rapidly — a pattern that implies active metabolites or downstream signaling are maintaining the effect after the parent compound clears. Those experiments used standard pain assays in rats and measured pain relief alongside pharmacokinetics to show the temporal mismatch between brain presence and analgesia.
Crucially, DFNZ did not produce the respiratory depression typical of fentanyl or morphine in the same models; instead, investigators recorded a moderate, sustained increase in brain oxygenation. That respiratory profile was observed consistently across doses that produced clear analgesia, making the lack of breathing suppression a repeatable signal rather than an isolated finding.
How DFNZ’s receptor activity departs from the old assumption
DFNZ is a nitazene‑derived mu‑opioid receptor superagonist — meaning it can produce very high receptor activation — but its net behavior resembles a safety profile usually seen with partial agonists. The authors describe this as a hybrid pharmacology: high intrinsic efficacy at the receptor combined with signaling patterns that do not recruit the pathways thought to drive respiratory suppression in the brainstem.
This combination challenges the long‑standing inference that greater mu‑receptor efficacy necessarily equals greater respiratory risk. DFNZ’s origins trace back to the mid‑20th century nitazene chemistry, but the NIH team modified the scaffold and characterized signaling bias and metabolite activity to explain why a superagonist can, in practice, behave more safely in animals.
Reward, dependence and how DFNZ compares with existing opioids
Behavioral and neurochemical signals point to a different addiction risk profile for DFNZ: rats did self‑administer the drug (showing some rewarding effect), but when DFNZ was switched to saline animals rapidly stopped seeking it — a contrast to the persistent drug‑seeking seen after removal of fentanyl or morphine. Microdialysis and dopamine assays showed slow, steady dopamine increases rather than the rapid spikes associated with cue‑triggered craving and relapse.
| Feature | DFNZ (rodent findings) | Typical opioids (fentanyl/morphine) |
|---|---|---|
| Analgesia duration | >2 hours despite brief brain presence | Duration correlates with brain exposure |
| Respiratory effect | No depression; increased brain oxygenation | Dose‑dependent respiratory depression |
| Dopamine pattern | Slow, sustained rise | Rapid spikes linked to cues |
| Self‑administration persistence | Stops quickly when replaced with saline | Often persists after removal |
| Tolerance / withdrawal | Minimal tolerance; little to no withdrawal | Tolerance and withdrawal common |
Development decisions, practical thresholds and stop signals
The NIH team, led by Dr. Michael Michaelides, plans further preclinical work to support an investigational new drug (IND) filing; key thresholds before human dosing include reproducible respiratory safety in non‑rodent species, clear pharmacokinetic/pharmacodynamic relationships for parent and metabolites, and toxicology studies adequate for regulators. For clinicians and trial designers, the immediate implication is that DFNZ could be tested first in controlled postsurgical pain settings where respiratory monitoring is standard.
If early human studies replicate the rodent safety signals — no measurable respiratory depression at analgesic doses and no rapid dopamine surges on neurochemical readouts — development could proceed toward broader trials in cancer or chronic pain. Stop signals that would halt progress include: clinically significant respiratory depression in phase 1, robust cue‑linked dopamine spikes or persistent drug‑seeking in primate models, or unforeseen toxicities in safety studies.
Short Q&A
When could human trials begin? The team must complete additional preclinical safety and tox work and file an IND; no human start date has been announced.
Could DFNZ replace methadone or buprenorphine for opioid use disorder? It’s speculative: the animal data suggest lower relapse risk, but clinical efficacy and safety for treating OUD would require dedicated trials and regulatory review.
What would be the clearest sign DFNZ is unsafe in people? Any dose‑related respiratory suppression in early human pharmacology studies would be a decisive stop signal, as would evidence of rapid cue‑linked dopamine spikes or significant withdrawal after repeated dosing.